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Abstract
Intravitreal injection is a common treatment in ophthalmology, but it can lead to
considerable patient anxiety and numerous complications. Lorentz-force actuated
needle-free jet injection has been shown to successfully deliver fluid to various layers of
skin, and, by its nature, may reduce intravitreal injection anxiety and complications.
The challenges of adapting current Lorentz-force actuated needle-free jet injection
technology to intravitreal injection were investigated using a previously developed jet
injection system. Two iterations of an intravitreal injection-specific control scheme
were designed, implemented, and tested. Several tools were developed in tandem with
the research, including intravitreal injection 3D reconstruction software, actuator-jet
transfer function generation software, and bench-top eye injection staging equipment.
From injection trials into ex vivo rabbit eyes, we find that needle-free jet injection
can be used for intravitreal drug delivery. The new system is capable of delivering
40 pL of fluid to the posterior vitreous humor, with an injection duration less than
100 ms and scleral entry site less than 350 pm in diameter. A relationship has been
developed between injection parameters and eye damage metrics that can be used for
future parameter optimization, minimizing damage to the eye.
Thesis Supervisor: Ian W. Hunter
Title: Hatsopoulos Professor of Mechanical Engineering
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Chapter 1
Introduction
Intravitreal injection is a necessary procedure for treatment of eye diseases such as
age-related macular degeneration [10], proliferative diabetic retinopathy [11], and
endophthalmitis [12]. The procedure demands constant focus and dexterity from
an ophthalmologist. Mistakes are uncommon but can lead to serious complications
[13] such as lens damage, retinal damage, infection, and even ocular explosion [14].
Repeated injections are often required for months or a patient's entire life, and patient
compliance with this regimen leads to better visual health. However, discomfort and
anxiety associated with the operation is common to all injections [15].
A cost-effective injection system that reduces the frequency of complications and
increases patient compliance would transform eye care, and the development of such
a system was the goal of this thesis project. This thesis explains current intravitreal
injection techniques, eye biomechanics, prior jet injection development, and eye ex-
perimentation methodology. Next, preliminary experiments with current jet injection
technology are analyzed. Finally, we present the design, development, and testing of
a new intravitreal jet injector and the future work needed to bring the device to its
full potential.
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Chapter 2
Background
2.1 Intravitreal Injection
2.1.1 Introduction
The vitreous body or humor occupies the majority of the volume of the human eye,
shown in Fig. 2-1. Several methods have been used for prolonged drug delivery to
the vitreous humor, such as topical application, implantable devices, microspheres,
and liposomes. However, regularly administered intravitreal needle injections remain
the most common because they are the most direct and immediate route of drug
delivery. The goal of an intravitreal injection is to deposit drug inside the vitreous
humor, while causing minimal damage to surrounding tissues, including the lens,
retina, cornea, choroid, and sclera.
2.1.2 Biomechanics
The structure of the eye in the injection area makes this type of injection more
difficult and risky than a typical intramuscular or intravenous injection. In a correctly
performed intravitreal injection, the needle pierces the sclera, choroid, and vitreous
humor, while remaining posterior to the limbus and ciliary bodies and anterior to the
ora serrata. This path is shown in Fig. 2-2. The ora serrata is the area where the
retina ends. In Fig. 2-3, the structure of the injection site is on the anterior side of
17
Figure 2-1: Diagram of the human eye from communications with Institut de la Vision
[1] & Sanofi Fovea; superior view of right eye.
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Figure 2-2: SolidWorks model of the human eye with the path of intravitreal injection
shown. (a) Complete eye from superior lateral view. (b) Cross-section of eye along
injection path. (c) Simplified injection site structure: (1) sclera, (2) choroid, (3)
retina.
the ora serrata, while the retina is on the posterior side.
The biomechanical properties of these structures have been studied previously. For
example, the force required by a 260.4 pm diameter needle (31-gauge) to penetrate
an enucleated sclera was found to be about 0.3 N [16]. Larger (lower gauge) needles
require more force, result in more reflux after the injection, and are associated with
more pain [17]. The sclera is about 0.5 mm thick [18], with a modulus of elasticity
of 2.3 x 106 N/m 2 [19]. In the injection area, the choroid is about five times less stiff
than the sclera and about three times less thick [20]. The sclera is thus the most
resistant layer for any injection to pierce.
The vitreous humor is a clear gel-liquid hybrid that fills the eye cavity posterior
to the lens. Its structure is a double-network, consisting of randomly spaced collagen
19
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Figure 2-3: Histology of the ora serrata, with the posterior eye to the left and the
anterior eye to the right. Edited image from the instructional materials of the Depart-
ment of Neurobiology, School of Medicine, University of California, Los Angeles[2].
To prevent damage to the retina, injection must occur anterior to the ora serrata.
20
fibers and macromolecules of hyaluronic acid [21]. It is believed that the hyaluronic
network is responsible for the vitreous resistance to sudden shock and that the collagen
network is responsible for the vitreous tensile strength.
Transport in the vitreous is estimated to be 30% convection and 70% diffusion for
small molecules like acid orange 8, with a molecular weight of 364.4 D and a half-life
in the vitreous on the order of hours [22]. However, modern (and most commonly
used) drugs such as bevacizumab (Avastin), with molecular weights above 1000 kD,
can have half-lives of four days. For high molecular weight drugs, convection is
estimated to be much more influential than diffusion [23]. Convection currents are
caused by several mechanisms in the eye, including aqueous outflow in the anterior
sections of the eye and vitreous outflow in the posterior. The result of a vitreous flow
simulation that agrees with experimental data on the rabbit eye is shown in Fig. 2-4.
Because high molecular weight drugs diffuse very slowly, positioning them in high
concentrations near a target site is ideal. Traditional intravitreal needle injections do
not have this capability.
2.1.3 Technique
Guidelines for intravitreal injection have been published, but technique still varies
considerably between ophthalmologists [24]. Normally, a 260.4 pm-412.8 pm diameter
needle (27- to 31-gauge) is inserted about 3 mm posterior to the limbus corneae (the
border of the cornea). Common injection volumes range from 50 pL to 150 pL. Before,
after, and during the injection, meticulous care must be taken in order to minimize
the risk of infection, of physically damaging the eye, and of causing the patient more
pain than necessary [25]. A demonstration of the injection step of the procedure is
shown in Fig. 2-5.
After an injection, a test for sensitivity to light and an intraocular pressure (lOP)
measurement are taken. Abnormalities in these tests or symptoms reported by the
patient are signs of complications with the injection. Complications are often only
discovered at a subsequent appointment while imaging the fundus or testing visual
acuity.
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Figure 2-4: Speed contour and velocity vector for vitreous flow simulation in a rabbit
eye, taken from J. Park et al. [3]. (Vitreous outflow of 0.1 plL/min) (A) Velocity
vector plot for aqueous humor generated from ciliary processes and cleared through
Schlemms canal. (B) Speed contour in anterior and posterior segments of the rabbit
eye.
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Figure 2-5: Frame from an intravitreal injection demonstration video created by
James Folk[4].
2.2 Needle-Free Jet Injection Technology
Lorentz-force actuated needle-free jet injection (JI) technology developed at the MIT
BioInstrumentation Lab [26] was identified as a promising solution to the complica-
tions and anxiety associated with needle intravitreal injection. The device works on
the principle of the Lorentz force, a force exerted on a charged particle moving in
a magnetic field. By running electrical current through a coil in a magnetic field, a
force is generated. This force is transmitted through a piston to accelerate fluid up
to velocities high enough to penetrate tissue.
A previous JI system is shown in Fig. 2-6. In the injector device, voltage is
controlled across a voice coil which slides along a fixed magnet. A LabVIEW [27]
program and data acquisition system actively monitor the position of the coil with a
potentiometer and adjust the voltage to follow a pre-set path. The coil is attached
to a syringe which ejects drug through a small nozzle at high speeds. The nozzle is
placed in contact with tissue and the injection is initiated with a button.
Much of the design work in this thesis builds on the previously-developed JI device
[5], the characteristics of which are discussed in the following sections.
23
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Figure 2-6: MIT Bioinstrumentation Lab's previous jet injector prototype. Picture
taken from A. Taberner et al. [5].(a) Hand-held injector. (b) Cutaway view of linear
Lorentz-force motor. (c) cRIO controller programmed using LabVIEW.
2.2.1 Electromechanical Design
The injector's chassis is steel and encloses the coil-magnet system. NdFeB magnets are
fastened to a steel backplate. A moving voice coil is created by winding copper wire
around a high performance polymer material which has been machined to slide along
the inside of the chassis. The performance material is also machined to connect to a
slide potentiometer and the syringe piston of the injector. The slide potentiometer
is used for real-time coil displacement measurement. The system was designed to
incorporate InjexTM injection ampoules (INJEX Pharma Ltd., Miama, FL), which
consist of a syringe and syringe piston. The syringe barrel is fastened to the front of
the device, and as the voice coil moves, the syringe piston, attached to the front of
the moving coil, ejects or draws in fluid. A system cutaway is shown in Fig. 2-7.
2.2.2 Control Design
A diagram of the control architecture is shown in Fig. 2-8. A trajectory is gener-
ated based on the velocities desired throughout the injection and the total desired
drug volume. The controller uses two components to follow the injection trajectory,
a proportional-integral (PI) feedback controller and a feed-forward command based
on velocity. The coil position is PI-controlled using the voltage from the slide po-
tentiometer as a feedback variable. Based on previous steady-state velocity-voltage
24
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Figure 2-7: Cutaway view of the jet injector, taken from A. Taberner et al. [6].
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Figure 2-8: Jet injector control architecture, taken from A. Taberner et al. [6].
relationship calibrations and the velocity of the desired trajectory, a feed-forward
voltage waveform is generated. Every time step, after controller calculations are
completed in an FPGA, the total of the position feedback and feed-forward voltage
are sent to the voltage input on a power amplifier. This amplifier drives the coil and
ejects liquid from the ampoule.
2.2.3 Capabilities
Using Lorentz-force actuated JI technology, the jet velocity can be actively changed
over the time of the injection by varying the current in the coil. Spring-loaded and
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Figure 2-9: Injection depth for various jet injections into post-mortem tissues, taken
from A. Taberner et al. [5]. The area of each circle represents the total desired
injection volume (10 p1L or 100 pL); the percentage quantifies the mean proportion of
the drug absorbed by the tissue, by weight.
compressed-gas jet injectors do not have this ability. For example, the injection
device can set a high velocity phase that pierces tissue followed by a low velocity
phase to deliver the bulk of a drug. By varying the velocities in these two phases,
a user can select the depth of the injection [28]. Depth of jet injection into tissues
with varying injection settings are shown in Fig. 2-9. Moreover, dynamic delivery
waveforms are possible using real-time position control. A representative waveform
from the previous prototype is shown in Fig. 2-10. With position control, injections
of set volumes are repeatable [5]. With previously tested devices, jets of fluid less
than 100 lim in diameter are possible. An entire 100 pL injection can take place in
less than 200 ms, followed by an automatic reload process. Injection velocities are
able to reach over 200 m/s. Finally, the device is user-friendly, because one button
can trigger the near-instantaneous injection waveform, requiring less dexterity than
a traditional syringe.
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Figure 2-10: Sample position waveform of MIT Bioinstrumentation Lab's previous
jet injector prototype, taken from A. Taberner et al. [5].
2.2.4 Applications to Intravitreal Injection
This technology was chosen for adaptation to intravitreal injections for a number of
reasons. The absence of a needle anywhere inside the orbit prevents accidental stick
wounds and decreases the risk of endophthalmitis. A velocity- and dosage-controlled
delivery is only possible with an actuator and feedback control system and could
ensure repeatable, accurate injections that target a specific depth in the eye. An
assistant may be able to perform these injections with the addition of a user-friendly
interface, saving valuable patient-ophthalmologist interaction time. Injections could
also be performed more quickly and with less footprint than a needle, reducing patient
anxiety and pain.
However, the structure of the eye in the injection path is much different than that
of skin, the target of past JI testing. Successful delivery to the vitreous humor would
require customization of the control strategy and possibly the nozzle geometry of the
jet injector.
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2.3 Intravitreal Jet Injection (IV JI) Previous Work
2.3.1 Accidental Injections
Because no jet injector has been approved for human intravitreal injection use, the
only examples of human IV JI are accident reports. In two reported instances, the
Dermojet jet injector has been used on the eyelid and accidentally pierced the sclera,
continuing into the vitreous [7] [29]. The resultant injury from an accidental injection
in 2009, shown in Fig. 2-11, caused diffuse vitreous hemorrhaging, which obscured
the retina and acutely blinded the patient. In the examination following the event,
the majority of the retina was found to be intact and the patient's IOP was normal.
By the next day, the hemorrhage had cleared, revealing two retinal tears, which
were treated. Ten months later, the tears had closed and the patient's vision was
restored. In 1977 an accidental injection caused a retinal tear but had no lasting
visual consequences. In both cases the injection entry and exit holes were at sites
posterior to the ora serrata, which resulted in retinal tearing. If the injection site and
speed could be controlled to eliminate entry and exit wounds being created, retinal
tears and hemorrhaging may not have occurred at all.
2.3.2 Microneedle-Assisted Jet Injection
The only previous work found on IV JI development is the hybrid needle-jet system
shown in Fig. 2-12 [8]. A microneedle (412.8 pm diameter, 27-gauge needle, protruding
0.1 mm from a flange) was fitted to the end of a Dermojet spring-powered jet injector.
When inserted into the sclera at the normal intravitreal injection site, the needle
penetrates less than 0.1 mm. The remaining piercing depth is eroded by the Dermojet
jet. Test injections of 200 pL were run on both dissected and live rabbit eyes. No
macroscopic or microscopic damage was reported. In vivo cross sections are shown
in Fig. 2-13. Although this injector is a promising example of IV JI, it still suffers
from many of the same disadvantages associated with needle injection, such as risk
of scleral damage and infection, likely patient discomfort (especially using a 412.8 pm
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Figure 2-11: Clinical images from am accidental intravitreal Dermojet injection, taken
from Y. Barak et al. [7]. (A) Small needle-like hole visible in the right brow area
(arrow). (B) Episcleral veins; injection mark is visible in the upper conjunctiva
surrounding the entry wound (arrow).
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Figure 2-12: The jet injector prototype (above) and microneedle with flange (below)
in magnification view, taken from G. Peyman et al. [8].
diameter needle), and needle contamination and replacement.
2.4 Experimental Eye Model
For various ocular disease models and biological research, an array of animal models
are appropriate, including micro-organisms, insects, fish, reptiles, birds, and mam-
mals [30].
For intravitreal injection studies targeted at human treatment, it is necessary to
use an eye model with dimensions on the order of the human eye. Animal models
commonly used for intravitreal injection studies include porcine [31], rabbit [32],
primate [33], and rodent [34]. However, the response of rodent models can vary
significantly from that of humans [34].
Although porcine and monkey models have anatomical structure more similar to
the human eye, rabbit eyes were ultimately chosen based on availability. Mouse eyes
were investigated but rejected as useful models. For the study in this thesis, the two
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Figure 2-13: Representative cross-sections of frozen rabbit eyes following in vivo in-
travitreal injection of blue dye, taken from G. Peyman et al. [8]. (A) Microneedle-
assisted jet injection (6.72 MPa). Inset shows bluish injection area. (B) Control
intravitreal injection using a 412.8 pm diameter needle (27-gauge) and syringe.
Rabbit Man
Anteroposterior Globe Dimension (mm) 16-19 24
Cornea Horizontal Diameter (mm) 15 11.7
Lens Thickness (mm) 7.6 4
Scleral Thickness (mm) 0.2-0.75 0.3-1.0
Scleral Young's Modulus (MPa) 0.78 2.3
Table 2.1: Comparison of human and rabbit eye properties. [30] [19] [20] [35]
most relevant differences in the human and rabbit eye anatomies are the lens size
(relative to globe size) and scleral properties. The lens size of the rabbit eye is larger
than the human lens relative to the size of the eye [30] as shown in Fig. 2-14. The
rabbit scleral stiffness is three times less than the human stiffness [35], but scleral
thickness is similar [30]. Table 2.1 lists relevant values for comparison.
Synthetic eye models were considered. Using a mold and contact lens, an injection
surface and vitreous humor can be simulated. Several contact lenses have properties
comparable to the sclera. However, due to the immediate success of the rabbit eye as
a model, the synthetic eye was not used.
2.5 Velocity Calculation Methodology
This thesis mentions four different types of velocity: potentiometer-measured coil
velocity, coil volumetric-estimated jet velocity, piston-tip volumetric-estimated jet
velocity, and electromechanics-estimated jet velocity.
Potentiometer-measured coil velocity is calculated from a discrete derivative of
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Figure 2-14: A scale diagram of the human eye (received in communications with
Institut de la Vision & Sanofi-Fovea, Paris) and a post-processed cryotomed cross-
section image of a rabbit eye used in this thesis. Shown in same scale.
the potentiometer-based position waveform. Position p(i) is measured every step i
using a relationship between the voltage output of the potentiometer system and
displacement. vc0 i at every step is then calculated as follows:
Vco (i) = p(i) - p(i - 1) (2.1)
tsample
where tsample is the intersample interval at which measurements were taken.
Coil volumetric-estimated jet velocity, used in the previous BioInstrumentation
Lab device, is an average jet velocity calculated based on the potentiometer-measured
coil velocity (vcosi), the diameter of the rubber piston tip (Dpiston), and the inner
nozzle diameter (Dnozzie). Essentially, the amount of fluid displaced by the piston
flows through the nozzle, creating a jet with an average velocity calculated as follows:
Vcoiijet(it) = ocjs; . (2.2)
Dnozzie
Piston-tip volumetric-estimated jet velocity uses the piston tip velocity instead
of the coil velocity. The piston tip velocity is measured directly using a high-speed
32
camera and a pixel interpolation video processing algorithm. This method is more
accurate than using coil velocity because it is closer to the piston-fluid interface and
not subject to the error induced by compression of the rubber piston tip. Calculation
of this velocity is as follows:
vt(i) = Dpist on (2.3)
Dnozzie
Electromechanics-estimated jet velocity is calculated for some intravitreal injec-
tions because the high-speed camera is used to film the eye instead of the piston tip,
but the coil volumetric-estimated jet velocity is too inaccurate. In this case, the jet
velocity may be estimated using the electromechanical properties of the system and
Bernoulli's Principle as follows:
Vemjet = ,P (2.4)
where Vemjet is the average jet velocity, p is the density of the fluid, and P is the
pressure in the ampoule. To estimate the pressure in the ampoule, the force on the
piston tip is calculated and divided by ampoule area. Piston tip force is estimated
by subtracting the force used to accelerate the coil system from the Lorentz force
generated by the coil. Combining these properties leads to the following calculation
of the pressure:
P = (KI - macoji)/Apiston, (2.5)
where K is the motor constant, I is the peak current passing through the coil, m is
the mass of the coil system, acoil is the acceleration of the coil system, and Apiston
is the area of the piston. The acceleration is approximated as constant when this
method is used and estimated using the rise time (trise) and peak coil velocity (Vpeak)
as follows:
acoi = Vpeak/trise. (2.6)
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The peak velocity and rise time are potentiometer-measured coil velocities.
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Chapter 3
JI Scleral Penetration Investigation
This chapter describes initial experiments performed to assess the effects of a high-
velocity jet stream on the eye. An earlier iteration of the JI system as described
in [5] was used to generate this jet stream and prove the feasibility of applying a
Lorentz-force actuated JI system to IV JI.
3.1 Design
The previous electromechanical and control system was used for the first iteration
of intravitreal injection testing. Eye mounts for each animal model were fabricated
to allow for convenient JI IV, and control parameters were calculated for intravitreal
injection in each animal model (discussed below). Four parameters were used to
generate each two-phase injection waveform for the system to follow: injection jet
velocity (vjet), injection jet duration (tjet), follow-through velocity (Vfollowthrough),
and total desired volume (Vdesired). Velocities used in this section are coil volumetric-
estimated jet velocities.
3.2 Testing
Two preliminary animal models were used for this iteration: mouse and rabbit.
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Figure 3-1: SolidWorks model of 3D printed eye mount for mouse eye injections.
30 mm in diameter.
3.2.1 Mouse Eye Model
Because of the immediate availability of mouse eyes, they were considered as a possible
preliminary animal model. The anterior thickness of mouse sclera has been measured
at 16.7 pm [36], two orders of magnitude thinner than the human sclera. Erosion depth
in injections into previous mediums has been somewhat linear with velocity within
an order of magnitude of the penetration velocity. Therefore, 10% of a common vjet
for penetrating skin (200 m/s) was used as a starting point for mouse eyes (20 m/s).
If the mouse eye was injected with a proportional volume of fluid to the human eye,
the amount injected would be 0.37pL, which is too small for the original injector to
deliver at a high speed. Various other values for Vde,,ied, between 2 pL and 20 pL,
were used instead.
A mount, shown in Fig. 3-1 was developed for holding seven mouse eyes in place
for injection trials. The mount was designed based on the diameter of mouse eyes
received, 3.7mm, with holes 3mm in diameter and 3D printed using Accura SI 40
resin in a Viper S12 3D printer made by 3D Systems.
With vjet of 20 m/s, mouse eyes were dyed blue on the outside as shown in Fig.
3-2, making it difficult to discern whether the eye was injected, subjected to dye
diffusion, or only dyed blue superficially. No entry hole was found under microscope
examination, so it was concluded that the expected 20 m/s could not pierce a mouse
eye.
Velocities were increased with further injections. With Vdesired at 20 1 L, vjet values
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Figure 3-2: Scale bars are 1 mm. (A) Mouse eye dyed blue after 20 m/s jet injection.
(B) Eye destroyed after 200 m/s 10 pL injection.
over 100 m/s were required to pierce the eyes. The waveforms for these injections were
not examined, but it is likely that 100 m/s was not reached, due to 20 pL being such
a small volume. Above 100 m/s, the eyes were often destroyed, as shown in Fig. 3-2.
This evidence supported the hypothesis that mouse eyes were too small and delicate
to be used with the previous injector. A new animal model, the rabbit, would prove
useful.
3.2.2 Rabbit Eye Model
To relate the Vjet required to break through the sclera to the vjet required to break
through the skin, the pressures required by a needle to pierce the sclera and skin
were calculated using the piercing force required divided by the surface area of the
needle head. The contact surface area of needles were estimated using nominal outer
and inner diameters. Using the force required by a 311.2 pm needle (30-gauge) to
puncture the human sclera [16], an approximate sclera piercing pressure of 1.02 MPa
was calculated. Using the force required by a PS-2 needle to pierce abdominal tissue, a
skin piercing pressure of 0.6 MPa was calculated. However, because the human sclera
is three times stiffer than the rabbit sclera, it was estimated that approximately half
of skin-piercing pressure was sufficient to pierce rabbit sclera, 0.34 MPa. Because
pressure is proportional to velocity squared in Bernoulli's Principle [37], and a typical
skin-piercing vjet is 200 m/s, a setting of 150 m/s (approximately 200 /S) was selected
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BFigure 3-3: SolidWorks assembly of (A) eye fixture, (B) base, and (C) FUTEK [9]
load cell. Diameter of base is 42 mm.
for vjet.
An inverse dome for holding rabbit eyes was modeled, 3D printed, and fitted to a
turned base of plastic. The stage was rotatable and could be fixed to a load cell as
shown in Fig. 3-3. The slit through half of the eye holder allowed eye fluid to flow
down the holder and acted as a window for a high speed camera to see through the
pupil unobstructed. Load cell measurement was added to the data acquisition system
to assess any effect load had on the injections.
The eyes were injected 2 mm posterior to the limbus. This dimension is 1 mm
shorter than in humans due to the larger cornea of the rabbit. Parameters 150 m/s
Vjet, 20 ms tjet, 50 m/s Vfollowthrough, and 40 pL Vdired resulted in injection. Three
more eye injections were carried out with varying parameters. tjet of 5 ms was not
sufficient to pierce the sclera, most likely because the jet injector did not reach peak
velocity in this short time. However, with a 200 m/s Vjet and a 10 ms tjet, eye pene-
tration was successful. As in needle injections, dye entering the eye was clearly visible
through the pupil. These eyes were frozen, sectioned temporally along the axis of the
injection, and examined. A representative photo of an injected eye is shown in Fig.
3-4.
Preliminary high-speed imaging was attempted using a high-speed camera (Vision
Research Phantom v9.0, Wayne, New Jersey [38]). Various lighting arrangements
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Figure 3-4: Coil voltage, jet velocity, and cross-section of rabbit eye injection. Scale
bar is 5 mm.
were unsuccessful; however, a backlit set-up was promising and offered a limited view
of the injection pillar forming. This method would be refined in later injections. All
in all, the rabbit model was comfortable to work with and was chosen as the animal
model for the next set of experiments.
3.3 Conclusions
Experimenting with the original jet injector gave insights that would define the design
for the rest of the project. The injections required a similar velocity to that of skin
in order to pierce the sclera. However, the vitreous and retina are soft and fragile.
This led to the predicted relationship shown in Fig. 3-5. The hypothesis was that a
high-velocity jet for a short amount of time may be able to pierce the sclera but not
contain enough momentum to damage the eye. Additionally, vfoIlowthrogh must be
high enough to maintain the entry hole created by the jet, but low enough to prevent
damage.
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Figure 3-5: Diagram of hypothesised injection result-jet time-jet speed relationship.
A short, high-velocity injection is ideal.
Directly enucleating the vitreous of the eye was unproductive, as the eye lost shape
quickly. Slow freezing left ice crystals that could be eliminated by quick freezing.
Cryotoming would be necessary for clear images.
The original device controller was most likely unable to follow velocity fast enough
to pierce but not damage the eye. A controller based on jet velocity as opposed to
jet position was hypothesized to perform better for this application.
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Chapter 4
Development of a Needle-Free
Intravitreal Injection Device
This chapter describes the development and testing of new control schemes that use
the linear Lorentz-force actuator for needle-free intravitreal injection. Two control
schemes were investigated: a bang-PD velocity controller, and a piston-tip estimation
feed-forward controller.
4.1 Device Requirements
The goal of a new device in this space is to eliminate disadvantages discussed in
Section 2.1 without adding risk or losing capabilities. This new system targets a
number of disadvantages that can be eliminated using jet injection technology:
1. Risk of injuring eye mechanically with needle
2. Risk of infection
3. Discomfort and anxiety
4. Creation of sharps waste
5. Requirement of time from ophthalmologist
6. Inability to deliver high concentrations to the posterior region of the eye
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A list of reasonable design goals were developed, preserving the functionality of
the current intravitreal injection process and targeting the previously mentioned dis-
advantages (listed in parenthesis):
1. Doesn't require insertion of foreign object into the sclera or vitreous (1)(2)(3)
2. Creates injection hole smaller than current needles (3)
3. Completes injection procedure faster than needle injection (3)(5)
4. Doesn't require sharps (4)
5. Adds depth-targeting functionality to inject to the posterior region of the eye
(6)
6. Doesn't damage eye structures, notably the lens, retina, choroid, and sclera
7. Doesn't significantly reduce efficacy of injected drug
8. Accurately injects desired drug volumes into the vitreous humor
Many similar requirements have already been fulfilled for intradermal, subcuta-
neous, and intramuscular injections using JI technology, but adapting the technology
to the eye is an interesting challenge.
4.2 Bang-PD Velocity- Controlled System
The first iteration of the new device retained most hardware features of the original
jet injector system. However, a very different two-phase controller was created, better
suited to the challenge of intravitreal injection.
4.2.1 Design
The system utilized the same Injex TM injection ampoules (INJEX Pharma Ltd. [39])
with jet orifices averaging 221 pm in diameter and reused the eye base stage shown
in Fig. 3-3. Several hardware components of the previous system were replaced for
the new system, but none of these changed the system's basic functionality. A pair
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Figure 4-1: Custom-made injection amplifier connector. Width of connector is 52 mm.
of power amplifiers (AE Techron 7224 [40]) in series were used to generate the high-
bandwidth voltage to control the coil. A similar FPGA and real-time interface (Na-
tional Instruments cRIO-9024 [41]) were used for device control, camera triggering,
and user input.
A control panel and vertical positioning stage were added to make the benchtop
device easy to test. An amplifier interface, shown in Fig. 4-1, was custom-developed
for the new system to allow the amplifier to be conveniently connected and discon-
nected from an injection device and reduce noise. A precision voltage reference (Texas
Instruments REF102 [42]) was added to increase the signal-to-noise ratio of the po-
tentiometer position measurement. A high-speed camera (Vision Research Phantom
v9.0 [38]) was mounted facing perpendicular to the path of injection with a macro lens
to obtain intraocular video through the pupil. When triggered from the FPGA, the
camera records at 6400 fps at a resolution of 192 x 192 pixels. Lighting was provided
by a 150 watt source (Dolan-Jenner Fiber-Lite A3200 [43]), front- and back-lighting
the eye. A photo of the complete intravitreal injection and analysis system is shown
in Fig. 4-2. A photo of the eye staging area of the intravitreal injection system is
shown in Fig. 4-3.
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Figure 4-2: Complete benchtop intravitreal injection system. (A) High-speed camera.
(B) Camera control software on laptop. (C) High-intensity lighting. (D) Rabbit eye
positioning stage. (E) JI injector on vertical stage. (F) Control panel. (G) FPGA
and real-time control and data acquisition device.
The control scheme used in an earlier version of the jet injector was replaced
to facilitate IV JI. The speed and duration of an injection jet as discussed are key
factors in penetration depth [5], which is essential for successful IV injection. In an
IV JI, the jet speed must be high enough to pierce the sclera [16], yet the jet duration
must be short enough to not damage the retina. To estimate the coil velocity, a
discrete derivative of the 100 kHz-sampled coil position was smoothed by a 10 kHz
Butterworth low-pass filter.
In the control scheme, an initial bang controller (rising phase of a bang-bang
controller) was used to reach a high coil velocity in minimum time. This stage was
followed by proportional-derivative (PD) control of velocity to a preset follow-through
velocity. Within 5% of the preset coil position (proportional to injection volume), the
controller transitioned into PD position control. PD control gain values were initially
set based on previously performed system identification and later tuned by ejections
of water into air. The controller can be represented by the block diagram or pseu-
docode in Fig. 4-4. Three parameters were used to generate each two-phase injection
waveform for the system to follow: bang injection jet velocity (vang), follow-through
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Figure 4-3: IV jet injector. Scale bar is 100 mm. (A) Injector height adjustment
stage. (B) Lorentz-force actuated jet injector. (C) 3D-printed artificial orbit for eye
mechanical support and positioning.
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velocity (Vfollowthrough), and total desired volume (Vdesired). The coil position corre-
sponding to the desired delivery volume, pset, is calculated using the potentiometer
displacement relationship.
bangvoltage
Controller State Switch
velP
+ + bang while ve< vi,
A velocity PD while position < (0.95)ps
-
+ position PD while time < timeout
while vest < Vbang do
voltage <- bangvoltage
end while
while position < (0.9 5 )pset do
voltage <- PDControl(vest, VfollowthroughvelP, velD)
end while
while timeout > 0 do
voltage <- PDControl (position, pset, pos P, posD)
end while
Figure 4-4: Block diagram and pseudocode of control algorithm. The controller
state switch progresses to the next state when the 'while' condition is false. vest
is the real-time estimated velocity, Vbang is the set bang controller velocity, voltage
is the voltage command to the amplifier, bangvoltage is a bang control parameter,
position is the position measured by the potentiometer, Vfollowthrough is the set follow-
through velocity, pet is the set injection position, velP, velD, posP, posD are control
parameters, time increases throughout the injection, and timeout is a preset injection
time limit.
Although Vbang and Vfollowthrough settings for the control system are stated as
potentiometer-measured coil velocities, it is useful to estimate the average velocity of
the fluid jet. Potentiometer-measured coil velocities agreed well with the low piston-
tip volumetric-estimated jet velocities of the follow-through phase of the controller.
However, during the bang phase of the controller, the fast system dynamics resulted
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in a large error between camera-measured and volumetric-estimated jet velocity. Be-
cause the high-speed camera was directed at the pupil during IV JI instead of the
piston tip, electromechanics-estimated jet velocity as mentioned in Section 2.5 was
used to characterize the peak velocity of the injection. Compared with high-speed
piston tip camera video, electromechanics-estimated jet velocities exhibited a peak
velocity RMS error of 7.8 m/s.
4.2.2 Bang-PD Velocity Controller Testing
The controller improved the velocity profile for low-duration high-velocity JI. From
rest, the bang controller reached coil velocities of 2.5 m/s within 1.5 ms, and the PD
velocity controller slowed the coil to the follow-through velocity within 1 ms, shown in
Fig. 4-5. The high-velocity segment of the injection lasted less than 2 ms, about half
the duration of the earlier controller's high-velocity jet. The PD position controller
activated when the position was within 5% of the set-point. The controller held the
set-point until the injection time was reached.
Bang control of the injector system overshot the target velocity, as shown in Fig. 4-
5, due to the controller lag and third-order Lorentz-force actuator system dynamics.
When switching to the follow-through velocity segment, the PD controller undershot
the set velocity, even reversing direction. Tuning the PD controller to undershoot
ensured that fall time was short, which is critical to minimize tissue destruction,
and the real jet velocity never dropped below zero (verified by high-speed camera).
The overshoot and undershoot were not repeatable, most likely due to the time-
varying dynamics of the system (i.e., ampoule degradation) and varying injection
initial conditions (i.e., initial compression or relaxation of piston tip). During the
follow-through phase the system exhibited periodic oscillations, possibly due to non-
linear friction of the ampoule.
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Figure 4-5: Representative injection results with bang-PD velocity controller. Set
parameters: 2.5 rn/s coil bang velocity; 0.2 rn/s coil follow velocity; 40 piL delivery
volume (4 mm set-point).
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4.2.3 Rabbit Eye Injection Testing
Nine rabbit eyes were obtained through the MIT Tissue Harvest Program using pro-
cedures approved by the MIT Committee on Animal Care and in accordance with
the NIH Guide for the Use and Care of Laboratory Animals. Explanted eyes were
refrigerated in saline solution for no more than 4 hours before the injection trial. In
each trial, 40 iL of 0.25% bromophenol blue dye solution was injected 3 mm from the
limbus cormeae at the pars plana, the recommended site for human IV injection [25].
A 3 mm distance from the limbus corneae was chosen for this trial because, although
the cornea of the rabbit is large, its pars plana is also farther posterior. Settings
for Vbang ranged from 2.04 m/s to 2.42 m/s and settings for Vfollowthrough ranged from
0.05 m/s to 0.20 m/s.
Immediately after injection, eyes were embedded in optimal cutting temperature
compound (Tissue-Tek O.C.T. Compound 4583, Torrance, CA) in liquid nitrogen.
The samples were wrapped in foil and stored at -20 C until needed. The resulting
O.C.T.-eye blocks were sectioned and imaged in 30 pm increments superior and per-
pendicular to the axis of injection using a cryostat vibratome (GMI Inc. Vibratome
UltraPro 5000, Ramsey, MN).
A typical injection time-line is shown in Fig. 4-6. No vitreal reflux was observed
after any injection, but sectioning revealed that 7 out of 9 eyes exhibited retinal
tearing. To numerically characterize the post-injection eye results, two metrics were
defined: retinal tear diameter and entry hole diameter. These metrics were measured
as shown in Fig. 4-7. Electromechanics-estimated jet velocity is used to describe the
peak jet velocity of each rabbit eye injection. Two injections resulted in no retinal
tearing, as shown in Fig. 4-8, and had peak jet velocities of less than 171 m/s and
follow-through velocities of less than 6.8 m/s.
To relate velocity profile characteristics to eye damage metrics, the peak velocity
and average follow-though velocity of each injection were recorded. Next, to isolate
the effects of each velocity, the data was divided into two groups: five injections with
similar peak velocities (161 m/s ± 8 m/s) and four injections with similar follow-
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Figure 4-6: Timeline of injection, showing high-speed camera images and velocity
profile. Peak jet velocity: 170 m/s; average follow-through velocity: 6.7m/s. Eye
exhibited no retinal tearing.
A B
Figure 4-7: Injection result measurement methodology. (A) Entry hole diameter
is measured as the largest width of choroid puncture in sections. (B) Retinal tear
diameter is measured as the largest width of detached retina in sections.
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Figure 4-8: IV JI exhibiting no retinal tearing. Scale bar is 5 mm. (Superior view of
cross-section, showing injection site and target.)
through velocities (6.45 m/s ± 0.41 m/s). Remaining eye injection results were not
used for analysis. For each isolation group, the jet velocities were plotted against
both eye damage metrics, shown in Fig. 4-9. The plots show a positive correlation
between tissue damage and increasing velocities. The results suggest that for some
follow-through jet velocity between 6.58 m/s and 28.9 m/s the follow-through phase
begins to cause retinal tearing. Likewise, for some peak velocity between 170 m/s and
201 m/s, the peak velocity jet begins to cause retinal tearing.
4.2.4 3D Injection Reconstruction
Penetrating depth, dispersion, and an estimate of the volume of drug delivered to
the eye can be calculated by reconstruction of a 3D model of the injected eye from
2D slices of the eye. This was accomplished with 30 prm section images of the in-
jected eyes, taken using a 50 mm compact-macro lens while being sectioned on a
cryotome. Custom image recognition software was developed in MATLAB@ [44] to
automatically differentiate between eye tissues and injection dye in these sections us-
ing hue-saturation-value ranges, a process shown in Fig. 4-10. Once these structures
were recognized on every eye section, the software reconstructed the features into a
3D representation of the injection result, shown in Fig. 4-11.
These 3D data can also give us insight as to where the injected fluid has highest
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Figure 4-9: Plots of two velocity profile characteristics vs. two eye damage metrics.
For varying follow-through velocities, the peak velocity is 161 m/s ± 8 m/s; for varying
peak velocities, the follow-through velocity is 6.45 m/s ± 0.41 m/s.
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Figure 4-10: Image recognition process visualized on one 30 prm section of eye. Axis
shown are in pixels (10 pixels is approximately 3.2 mm. (Top-left) Raw image of
sectioned eye. (Top-right) red-green-blue image visualization after being converted to
hue-saturation-value color representation. (Bottom-left) Region of image recognized
as blue dye. (Bottom-right) Region of image recognized as eye structure.
concentration. This is most useful within the vitreous, where the visual properties
of the dye are most uniform. Challenges still exist, such as accounting for the dye
appearing darker in the sclera than it does in the vitreous, due to natural tissue
pigment. Also, in Fig. 4-11 the effects of imperfectly aligned sectioning can be seen
where the inside of the eye structure exhibits ridges. The visual 3D reconstruction
technique is not an exact tool yet, but it allows us to visualize and analyze the data
in an entire new dimension. For example, in Fig. 4-11, it is clear that dye travelled
to and stopped at the target site at the back of the eye.
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Figure 4-11: Reconstructed eye structure (blue) and dye (red). Scale bar is 5 mm.
(A) Dye around entry site. (B) Dye at target site. (C) Structures recognized as eye
tissue.
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Figure 4-12: Comparison of the volumetrically estimated volume delivered (left) and
volumetrically estimated jet speed (right) from the shaft potentiometer (blue) and
the piston tip high-speed camera (green).
4.2.5 Dynamics-Induced Jet Speed Error
The compression of the piston tip during an injection is substantial. Earlier tests of
the device have also shown that the ampoule itself strains noticeably. Together, these
two dynamic elements make the volumetric estimations from the coil position very
error prone, especially for the short, high-velocity jets that need to be achieved in IV
JI.
To measure the piston tip-induced error, the high speed camera recorded video
at 51,282 fps while pointed at the piston tip during an ejection of water into air.
After injection, custom video processing software was used to calculate the piston
tip position in each frame. Displacement resolution similar to the potentiometer
displacement resolution was reached by interpolating the distance travelled between
the center of pixels. The resulting volumetric estimation comparisons showed that
the coil peak velocity measurement can overestimate the piston tip peak velocity by
more than 300%. Equally important, the piston tip spends a prolonged period at
high velocity due to the feedback loop that maintains a steady shaft velocity. A
sample comparison of the coil-measured and piston tip-measured values is shown in
Fig. 4-12. To combat the adverse effect this phenomenon has on the eye interface jet
speed, a new controller was needed.
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4.2.6 Conclusions
These injections showed that IV JI can be accomplished using a pre-existing linear
Lorentz-force actuated jet injector with the addition of a bang-PD velocity controller.
As predicted, Fig. 4-9 indicates that low peak and follow-through velocities reduce
retinal tearing. Entry hole diameter is also positively correlated with both velocities
but exhibits a higher deviation between injections. Four eyes had entry hole diameters
less than 400 pm, within the range of needle sizes commonly used in intravitreal
injections. This is important, as pain and drug reflux have been shown to increase
with larger needles [17] and may similarly increase with larger IV JI entry holes.
Moreover, the IV JI duration is less than 100 ms, minimizing patient discomfort and
procedure time.
Eye sections with and without retinal tearing suggest that IV JI can target the
fovea and optic nerve, as shown by the dye concentration in Fig. 4-8. In a needle
injection, delivery to this area relies on convection and diffusion, but much of the
drug will be transported to areas other than the target, as shown in Fig. 2-4. Higher
concentrations of drug near the target site are favorable because they reduce the
total amount of drug needed, therefore reducing the effect of the drug on non-target
areas [45].
4.3 Piston Tip Estimation Feed-Forward System
The goals of this iteration were to improve controller performance and post-IV JI
analysis. The previous iteration suggested that better controller performance (i.e.
more accurate following of high-velocity short-duration jets) leads to more repeatable,
less damaging injections.
4.3.1 Design
As shown in Fig. 4-12, substantial piston compression caused a large error between
coil position and piston tip position. To control the position of the piston tip, a coil-
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Figure 4-13: Measuring method for transfer function development.
tip transfer function was required. The data acquisition set-up from Section 4.2.5
was used to record data for developing a transfer function. The previous bang-PD
controller was used to generate the waveforms used for analysis. As shown in Fig. 4-
13, this resulted in two time-dependent waveforms, coil displacement and piston tip
displacement by which to fit a transfer function for the system.
It was determined with sensitivity analysis that a 2nd-order linear model relating
coil displacement and piston tip displacement, coupled with a piston tip damping
term, was sufficient for predicting the motion of the system. This model was repre-
sented by the following differential equation:
Xtjp = m(xcoa - xtip) + b(.kcoa - ktip) + k|xtjj1tp,, (4.1)
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where m, b, and k are model parameters (unrelated to their classical dynamics mean-
ings) and xcoil and xt, are the displacement of the coil and tip, respectively, from
their starting positions.
An iterative optimization process, shown in Fig. 4-14, was used to calculate the
model parameters. The MATLAB@ function lsqcurvefit was used as a fast algorithm
for this process. To begin the process, three parameters (m, b, and k) were guessed.
A simulation was run to find the sum of squared error between the camera measured
tip displacement and the simulation tip displacement. The previous guesses were
then refined in trust-region-based optimization to minimize the sum of squared error.
This guess-check repeated until the change in error was below a threshold (0.0001%).
Sensitivity analysis revealed the importance of each transfer function term in correctly
predicting the piston tip displacement, shown in Fig. 4-15.
Theoretically, the position of the coil throughout a real-time injection can be
transformed by the model to predict the piston tip position. This real-time system
could then be controlled in a closed-loop fashion. However, in reality the necessary
calculations to update the system estimation created significant lag and required more
gates than available on the controller FPGA. For this reason, it was decided to pre-
generate a coil state waveform that, when used to simulate piston tip state, results
in a desired piston tip waveform. Using a controller with high gain, a simulated
injection was run in which the coil displacement was controlled so that the simulated
tip displacement followed the desired tip displacement, as shown in Fig. 4-16. The
desired tip displacement waveform was created using the same four parameters as
the original system: injection jet velocity (vjet), injection jet duration (tjet), follow-
through velocity (Vfollowthrough), and total desired volume (Vesired).
The results of the simulation were used to generate a full state feed-forward wave-
form to achieve desired piston tip displacement. A compensation command was
created based on desired coil acceleration, damping from coil friction, and piston tip
compression forces. Position and velocity waveform control corrected for error during
the injection. An example of the final waveforms used by FPGA control is shown in
Fig. 4-17.
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Figure 4-14: Method of determining coefficients for the coil displacement to tip dis-
placement transfer function.
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59
'I
C(a
O
4)E
0
0
4-
E3
E2 Desired Tip Displacement
.0 Simulated Tip Displacement
-o Simulated Coil Displacement
0
0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18
Time (s)
Figure 4-16: Block diagram and graph of simulation control for developing a desired
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Figure 4-17: Graphs of three signals sent to FPGA for control, including the desired
coil displacement, desired coil velocity, and a compensation command. The compen-
sation command was the estimated input voltage required to follow the desired coil
trajectory.
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The FPGA was programmed to read the waveforms and output a voltage signal
to the amplifier which is the sum of the displacement error multiplied by the P
gain, the velocity error multiplied by the D gain, and a compensation command
signal multiplied by compensation gain. These gains were manually tuned (starting
from theoretically predicted values) to result in optimal waveform following. The
calculation and output loop ran at 50 kHz, and the real-time velocity was predicted
using a discrete derivative processed by a 2nd order 10 kHz Butterworth low-pass
filter [46], resulting in a 1/2 attenuation of the real velocity at 10 kHz. Because
our desired jet velocity time was 1 ms, we predicted minimal attenuation of error
correction. The FPGA state-following algorithm is shown in Fig. 4-18. New InjexT M
ampoules were used for this section, with diameters averaging 193 pm.
4.3.2 Tip Estimation Controller Testing
The new controller successfully improved response of piston tip displacement using
estimation techniques. As shown in Fig. 4-19, the desired path is followed by the
coil but not by the piston. This is opposed to Fig. 4-20, where the estimated tip
displacement is controlled, resulting in tip displacement waveform following.
The estimation controller exhibited a mean RMS error of 0.11 mm over 10 in-
jections at vjet 200 m/s; tjet 1 Ms; Vfollowthrough 5 m/s; Vdeierd 40 pL. If the desired
displacement in the bang-PD controller is taken to be the desired tip displacement,
the bang-PD controller exhibited RMS errors four times this amount. However, the
controller still has room for improvement. The envelope plot shown in Fig. 4-21
shows the repeatability of the controller. As we zoom to the most dynamic section of
the injection in Fig. 4-22, clear oscillations are seen about the set point.
4.3.3 Analysis Improvements
Several diagnostics are routinely run before and after needle eye injections, includ-
ing IOP measurement, vision tests, and ophthalmoscope inspection. Additionally,
before and after jet injection trials for other tissues types, samples are weighed to
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E unfiltered discrete derivative
Figure 4-18: Diagram of full-state control algorithm, programmed in LabVIEW. The
phase lag of the Butterworth filter was acceptable at the frequencies required for good
trajectory following. (found to be < 5 kHz).
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Figure 4-21: Tip estimation controller air injection trials. The video analysis software
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Figure 4-22: Zoomed section of dynamic region of Fig. 4-21.
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estimate the total injection volume. Incorporating some of these techniques into IV
JI experiments was one goal of this design iteration.
Before an IV JI trial, a sample was weighed and measured for IOP with a Shiotz
tonometer (Riester 5112, Jungingen, Germany). Before weighing, the injection site
of the eye was dried using a cotton wipe. After the injection, the injection site was
again dried, the eye was weighed, measured for IOP, and inspected visually using a
miniature ophthalmoscope (Riester 3012, Jungingen, Germany). Because we lacked a
Schiotz tonometer calibration for rabbit eye IOP, all IOP measurements were relative.
A 20 g mass was added to the Schiotz tonometer because the shape of the rabbit eye
was not sufficiently deflected using the supplied masses for humans (up to 10 g).
4.3.4 Rabbit Eye Injection Testing
Eyes were injected in the same fashion as Section 4.2.3, except injection trials were
performed within 1 hour of explanting using the new controller. The rabbits used in
these studies had been given heparinized saline IV for several hours beforehand. Be-
cause the controller exhibited repeatable piston-tip following, controller parameters
Vjet, tjet, VfoIlowthrejgh, and Vdesired were used for comparing eye injections. Several
injections were non-penetrating, corresponding to Vjet settings less than or equal to
240 m/s and tjet settings of 1 ms. It was found that a 240 m/s vjet and 1.5 ms tjet re-
peatedly penetrated eyes, and six injections were performed with varying Vfollowthrojgh
settings and 40 pL Vdesired. These eyes were sectioned and measured for the metrics
in Section 4.2.3. The results of these injections are plotted in Fig. 4-23.
Results suggested minimal influence of vfollowthrough at a vjet of 240 m/s on both
retinal tear diameter and entry hole diameter. As shown in Fig. 4-24, dye from
one segment of the waveform reached the back of the eye, and dye from another
segment remained in the entry area of the eye. One hypothesis was that the high-
velocity stream reached and tore the retina, while the follow-through stream released
medicine into the vitreous without penetrating to the back of the eye. This suggested
that at lower Viet and longer tjet, such as 200 m/s for 1.5 ms, reliable non-damaging
injection may occur. 3D injection reconstruction from eye sectioning, shown in Fig. 4-
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Figure 4-23: Retinal tear diameter and entry hole diameter as a function of
Vf ollowthrough- Vjet 240 m/s; tjet 1.5 ms; Vdesired 40 iL.
25, illustrated that the bulk of dye delivered did not travel to the back of the eye,
supporting the jet speed tearing hypothesis.
Energy put into the injection system was calculated by integrating the power at
every time step of the injection. The power at each step was calculated by multiplying
the amplifier voltage (Vamp) and current (Iamp). The energy used in same-parameter
injection trials with torn and non-torn retinas differed by less than 5%, as shown
in Fig. 4-26. This may indicate that varying biomechanical properties due to pre-
injection treatment and handling (i.e. heparinization), not poor controller repeata-
bility, were responsible for the distribution of retinal tearing among injections with
the same parameters. This suggests that the injection parameters used lie in a region
in which injections begin to cause damage.
Improvements in analysis were only used for the first six penetrated eyes, due to
unrepeatable weighing with evaporation and steady IOP. By weighing several samples
after sitting untouched for 5 minutes, minimum mass evaporated during a single
protocol trial was estimated to be 19 mg with deviation on the same order as the
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Jet speed dye
Figure 4-24: Hypothesized two-segment waveform effect on retinal tearing.
67
Entry Site
C
Entry Site
Figure 4-25: 3D reconstruction of eye structure and dye using 30 Pm sections. The
bulk of the injected dye did not reach the retinal tearing site. Scale bar is 10 mm.
(A) Anterior medial view. (B) Posterior medial view. (C) Superior view.
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Figure 4-26: Energy comparison of two injections with the same parameters, one
causing retinal damage, and the other leaving the retina intact.
mass of our injection volumes, rendering the metric unreliable for estimating mass
injected. The first six penetrating injections had no effect on IOP at the resolution
of the Schiotz tonometer, suggesting that differences in IOP are most accurately
determined on live animals. The ophthalmoscope was subjectively useful, aiding in
pre-sectioning injection examination. However, with our current level of experience
using the miniature ophthalmoscope, we were unable to assess retinal damage before
sectioning.
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Chapter 5
Conclusions and Future Work
As of the last iteration of the IV JI, reliable needle free jet injection was not accom-
plished. However, several large strides were made in the direction of reliable injections.
First, a controller was developed that allows the jet injector to more closely follow a
jet velocity trajectory, especially for small volumes and high velocities. Second, stag-
ing and analysis tools developed in this thesis have provided insight into the modes of
eye damage and the effects of altering various injection parameters. Finally, using this
information, injection trials have steadily become more reliable and are expected to
continue on this trend with future work. These injection trials have also highlighted
several of the advantages of adapting jet injection technology to intravitreal injection
stated in Section 4.1.
It is likely that reliable IV JI can be achieved using the hardware and software
developed in this thesis, merely by making the parameter adjustments suggested in
Section 4.3.4. If it is necessary to make further hardware or software changes, future
work will focus on improving controller performance, injector mechanical design, and
parameter selection. At the moment, the controller exclusively uses the coil position-
piston tip transfer function for its feed-forward model. With high-speed fluid flow
measuring techniques such as particle image or laser Doppler velocimetry, a model
from coil position directly to jet velocity can be developed. Moreover, the addition
of adaptive control will improve trajectory following from injection to injection. Me-
chanically, redesigning the ampoule nozzle geometry may decrease damage to the eye
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by reducing the divergence and diameter of the exit stream. Finally, an optimized
Lorentz-force actuator and a faster FPGA and real-time interface may improve control
response and capabilities, increasing the options available for IV JI control.
72
Chapter 6
Bibliography
[1] Institut de la Vision, Paris, France. www. institut-vision. org.
[2] "Neurobiology 104 histology and cell biology - ora serrata histology." instruc-
tional material from Department of Neurobiology, School of Medicine, Univer-
sity of California, Los Angeles at http://neuromedia.neurobio.ucla.edu/
campbell/eyeandear/wp-images/175_oraserrata.gif.
[3] J. Park, P. M. Bungay, R. J. Lutz, J. J. Augsburger, R. W. Millard, A. S.
Roy, and R. K. Banerjee, "Evaluation of coupled convective-diffusive transport
of drugs administered by intravitreal injection and controlled release implant,"
Journal of Controlled Release, vol. 105, no. 3, pp. 279-295, 2005.
[4] J. C. Folk, "Eye intravitreal injection technique." instructional video at http:
//www.medicalvideos .us/play.php?vid=1964, Aug. 2010.
[5] A. Taberner, N. C. Hogan, and I. W. Hunter, "Needle-free jet injection using real-
time controlled linear lorentz-force actuators," Medical Engineering & Physics,
2012, in press.
[6] A. J. Taberner, N. B. Ball, N. C. Hogan, and I. W. Hunter, "A portable needle-
free jet injector based on a custom high power-density voice-coil actuator," in
Engineering in Medicine and Biology Society, 2006. EMBS '06. 28th Annual
International Conference of the IEEE, pp. 5001-5004, 2006.
73
[7] Y. Barak, M. D. Amiran, E. Fineberg, and Y. Lang, "Perforating eye injury
caused by a dermojet syringe," Archives of Dermatology, vol. 145, no. 8, pp. 958-
960, 2009.
[8] G. A. Peyman, K. Hosseini, and M. Cormier, "A minimally invasive jet injector
for intravitreal and subconjunctival injection," Ophthalmic Surgery, Lasers &
Imaging, vol. 43, no. 1, pp. 57-62, 2012.
[9] Futek, www.futek. com.
[10] P. V. Algvere, B. Sten, S. Seregard, and A. Kvanta, "A prospective study on
intravitreal bevacizumab (avastin) for neovascular age-related macular degener-
ation of different durations," Acta Ophthalmologica, vol. 86, no. 5, pp. 482-489,
2008.
[11] J. 0. Mason, P. A. Nixon, and M. F. White, "Intravitreal injection of beva-
cizumab (avastin) as adjunctive treatment of proliferative diabetic retinopathy,"
Americal Journal of Ophthalmology, vol. 142, no. 4, pp. 685-688, 2006.
[12] G. Sunaric-Mgevand and C. J. Pournaras, "Current approach to postopera-
tive endophthalmitis.," The British Journal of Ophthalmology, vol. 81, no. 11,
pp. 1006-1015, 1997.
[13] C. Shima, H. Sakaguchi, F. Gomi, M. Kamei, Y. Ikuno, Y. Oshima, M. Sawa,
M. Tsujikawa, S. Kusaka, and Y. Tano, "Complications in patients after intravit-
real injection of bevacizumab," Acta Ophthalmologica, vol. 86, no. 4, pp. 372 376,
2008.
[14] J. D. Bullock, R. E. Warwar, and W. R. Green, "Ocular explosion during cataract
surgery: a clinical, histopathological, experimental, and biophysical study.,"
Transactions of the American Ophthalmological Society, vol. 96, pp. 243-281,
2008.
[15] P. Y. S. Chua, I. Mitrut, A.-M. Armbrecht, A. Vani, T. Aslam, and B. Dhillon,
"Evaluating patient discomfort, anxiety, and fear before and after ranibizumab
74
intravitreous injection for wet age-related macular degeneration," Archives of
Ophthalmology, vol. 127, no. 7, pp. 313-316, 2009.
[16] J. S. Pulido, M. E. Zobitz, and K.-N. An, "Scleral penetration force requirements
for commonly used intravitreal needles," Eye, vol. 21, pp. 1210-1211, 2007.
[17] J. S. Pulido, C. M. Pulido, S. J. Bakri, C. A. McCannel, and J. D. Cameron,
"The use of 31-gauge needles and syringes for intraocular injections," Eye, vol. 21,
pp. 829-830, 2007.
[18] T. W. Olsen, S. Y. Aaberg, D. H. Geroski, and H. F. Edelhauser, "Human sclera:
Thickness and surface area," American Journal of Ophthalmology, vol. 125, no. 2,
pp. 237-241, 1998.
[19] T. R. Friberg and J. W. Lace, "A comparison of the elastic properties of human
choroid and sclera," Experimental Eye Research, vol. 47, no. 3, pp. 429-436,
1988.
[20] R. E. Norman, J. G. Flanagan, S. M. Rausch, I. A. Sigal, I. Tertinegg, A. Eilaghi,
S. Portnoy, J. G. Sled, and C. R. Ethier, "Dimensions of the human sclera:
Thickness measurement and regional changes with axial length," Experimental
Eye Research, vol. 90, no. 2, pp. 277-284, 2010.
[21] J. Black, Handbook of Biomaterial Properties. Thomson Science, 2-6 Boundary
Row, London SE1 8HN, UK: Chapman & Hall, 1 ed., 1998.
[22] J. Xu, J. J. Heys, V. H. Barocas, and T. W. Randolph, "Permeability and diffu-
sion in vitreous humor: Implications for drug delivery," Pharmaceutical Research,
vol. 17, 2000.
[23] C. G. Wilson, L. E. Tan, and J. Mains, "Principles of retinal drug delivery
from within the vitreous," in Drug Product Development for the Back of the Eye
(U. B. Kompella, H. F. Edelhauser, and D. J. A. Crommelin, eds.), vol. 2 of
AAPS Advances in the Pharmaceutical Sciences Series, pp. 125-158, Springer
US, 2011.
75
[24] D. R. Anijeet, R. J. Hanson, J. Bhagey, and R. A. Bates, "National survey of
the technique of intravitreal triamcinolone injection in the united kingdom," Eye,
vol. 21, pp. 480-486, 2006.
[25] J. F. Korobelnik, M. Weber, S. Y. Cohen, and E. Panel, "Guidelines for intrav-
itreal injections," Journal Franais DOphtalmologie, vol. 32, pp. el-e2, 2009.
[26] B. Hemond, "A lorentz-force actuated controllable needle-free drug delivery sys-
tem," Master's thesis, Massachusetts Institute of Technology, Cambridge, Mas-
sachusetts, Feb. 2006.
[27] National Instruments LabVIEW, www. ni. com/labview/.
[28] D. Wendell, B. Hemond, N. Hogan, A. Taberner, and I. Hunter, "The effect of
jet parameters on jet injection," in Engineering in Medicine and Biology Society,
2006. EMBS '06. 28th Annual International Conference of the IEEE, pp. 5005-
5008, 2006.
[29] H. T. Perry, B. T. Cohn, and J. S. Nauheim, "Accidental intraocular injection
with dermojet syringe," Archives of Dermatology, vol. 113, no. 8, p. 1131, 1977.
[30] P. A. Tsonis, ed., Animal models in eye research. Academic Press, 2008.
[31] N. Lassota, J. U. Prause, E. Scherfig, J. F. Kiilgaard, and M. La Cour, "Clinical
and histological findings after intravitreal injection of bevacizumab (avastin) in
a porcine model of choroidal neovascularization," Acta Ophthalmologica, vol. 88,
no. 3, pp. 300-308, 2010.
[32] S. J. Bakri, J. D. Cameron, C. A. McCannel, J. S. Pulido, and R. J. Marler,
"Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit
model," American Journal of Ophthalmology, vol. 142, no. 1, pp. 162-164, 2006.
[33] P. Heiduschka, H. Fietz, S. Hofmeister, S. Schultheiss, A. F. Mack, S. Peters,
F. Ziemssen, B. Niggemann, S. Julien, K. U. Bartz-Schmidt, and U. Schraer-
meyer, "Penetration of bevacizumab through the retina after intravitreal in-
76
jection in the monkey," Investigative Ophthalmology & Visual Science, vol. 48,
pp. 2814-2823, 2007.
[34] F. Lu and R. Adelman, "Are intravitreal bevacizumab and ranibizumab effective
in a rat model of choroidal neovascularization?," Graefe's Archive for Clinical
and Experimental Ophthalmology, vol. 247, pp. 171-177, 2009.
[35] J. C. Downs, J. K. Suh, K. A. Thomas, A. J. Bellezza, C. F. Burgoyne, and R. T.
Hart, "Viscoelastic characterization of peripapillary sclera: material properties
by quadrant in rabbit and monkey eyes," Journal of Biomechanical Engineering,
vol. 125, pp. 124-131, 2003.
[36] R. Beuerman, A. Barathi, S. Weon, and D. Tan, "Two models of experimental
myopia in the mouse," Investigative Ophthalmology & Visual Science, vol. 44,
p. 4338, 2003.
[37] Encyclopdia Britannica. Encyclopdia Britannica Online., ch. fluid mechanics.
Encyclopdia Britannica Inc., 2012.
[38] Vision Research, Wayne, New Jersey. www. visionresearch. com.
[39] Injex Pharma Ltd., Miama, FL. www. injex. com.
[40] AE Techron, Elkhart, IN. www. aetechron. com.
[41] National Instruments, Austin, TX. www. ni. com.
[42] Texas Instruments, Dallas, TX. www. ti. com.
[43] Dolan-Jenner, Lawrence, MA. www.dolan-jenner. com.
[44] MathWorks MATLAB, www. mathworks. com/products/matlab/.
[45] S. Ding, "Recent developments in ophthalmic drug delivery," Pharmaceutical
Science & Technology Today, vol. 1, no. 8, pp. 328 - 335, 1998.
[46] S. Butterworth, "On the theory of filter amplifiers," Experimental Wireless &
the Wireless Engineer, vol. 7, pp. 536-541, 1930.
77
